Capricor Shares Jump 8% After FDA Decision Timeline for Deramiocel Extended by 3 Months

CAPR Capricor Therapeutics Inc

$6.59 -4.22%

View chart & analysis →

1. 1Capricor Therapeutics (CAPR) shares rose 8% after the FDA extended the decision timeline for deramiocel by three months
2. 2The deadline was pushed from August 22 to November 22, prompted by key supplemental BLA submissions including HOPE-3 24-month data
3. 3H.C. Wainwright maintained a Neutral rating, noting that the risk of rejection remains high following the advisory committee's negative vote

Source Bloomberg +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →